The settlement removes a major litigation distraction, allowing Johnson & Johnson to redirect resources toward its core pharmaceutical and medtech segments, which generate $85B in annual revenue.
According to Biotech Intelligence Brief's own aggregated record, in the last 24 hours we tracked 4 stories — 25% positive, 25% negative, 50% neutral sentiment, averaging 6/10 impact. Most recent as of .
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived, or our full coverage statistics for the all-time breakdown.
Oral HIF-2α inhibitor casdatifan posted durable responses in the ARC-20 phase 1 trial of 127 heavily pretreated ccRCC patients, published in Nature. The data intensifies competition in the HIF-2α space, where Merck’s belzutifan is already approved, and sets the stage for pivotal trials.
The death of a young patient in a Chinese gene-editing trial, hidden from a subsequent Nature publication, sends shockwaves through the biotech sector. Industry leaders must grapple with the implications for gene therapy research integrity, funding, and the race to deliver transformative neurological treatments.
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
The potential elimination of 280E taxes on cannabis businesses could inject over $2 billion annually into the biotech sector, accelerating cannabinoid drug development. MMJ International Holdings' latest press release quantifies the stakes.
The Trump administration's use of keyword filters to cancel nearly $2 billion in UC research grants dealt a heavy blow to biomedical innovation, affecting studies from gene therapy to clinical trials. The legal admission exposes the unscientific basis for the terminations.
Colossal Biosciences is reportedly eyeing a valuation of $20 to $30 billion — more than double its 2025 mark — as it transitions from a de-extinction curiosity into a broad gene-editing and AI platform with multiple revenue streams, spinouts in plastics and fertility tech, and growing conservation contracts.
With 80% of new Ebola cases from unknown chains and the rare Bundibugyo strain lacking any approved vaccine or treatment, this outbreak exposes a critical gap in the biopharma pipeline and may catalyse urgent R&D investment.
The acquisition transforms Samsung Biologics into a multi-modality CDMO leader, adding industrial-scale peptide synthesis to its existing biologics platform. For biotech and pharma developers, this consolidation offers a one-stop manufacturing solution and intensifies competition among peptide CDMOs like Bachem and CordenPharma.
Our editorial methodology, AI pipeline, and quality standards for Biotech intelligence.
Essential terminology and concepts you need to understand Biotech news.
Key trends, market forces, and developments shaping the Biotech landscape.
About this site
Biotech Intelligence Brief is a free daily intelligence briefing focused on biotech and pharmaceutical — covering FDA approvals, clinical trials, drug development, and industry deals.
Found an error? Email hello@getbiobrief.com with the story URL and what's wrong — we review and respond within 48 hours, and verified errors are fixed at the source record. See our editorial standards and changelog for our full corrections process.
Biotech Intelligence Brief is a free daily intelligence briefing focused on biotech and pharmaceutical — covering FDA approvals, clinical trials, drug development, and industry deals. Every story is scored for impact, categorized, and enriched with entity tracking so you can follow the companies, people, and trends that matter.
Stories are curated and published daily using an editorial pipeline that monitors dozens of sources, scores each story for impact and relevance, and removes duplicates. The homepage always shows the most important recent developments.
Stories are sourced from FDA filings, clinical trial registries, peer-reviewed journals, and pharma industry publications. Each story is verified across multiple outlets before being included in the briefing.
Yes, Biotech Intelligence Brief is completely free. No account, no subscription, no paywall. You can read every story, explore trending entities, and browse category archives without any signup.